Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia

Health Economics Review

Volumn 1, Issue 1, 2011, Pages 1-9

  Plagemann, Thomas ^a   Prenzler, Anne ^b   Mittendorf, Thomas ^a  

^a Herescon GmbH Health Economic Research and Consulting   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXYCHLORIDE; CALCI GRY; CALCIUM; CALCIUM ACETATE; CALCIUM ACETATE PLUS MAGNESIUM CARBONATE; CALCIUM BASED PHOSPHATE BINDING AGENT; CALCIUM CARBONATE; CALCIUMACETAT NEFRO; CALCIUMACETAT PRORENAL AM; CC NEFRO; DREISACARB; LANTHANUM CARBONATE; MAGNESIUM; MISCELLANEOUS DRUGS AND AGENTS; OSVAREN; PHOS EX; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALUMINUM OVERLOAD; ANEMIA; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MAGNESIUM BLOOD LEVEL; MEDICATION COMPLIANCE; MONOTHERAPY; OSTEOMALACIA; PATIENT COMPLIANCE; PERCEPTION DISORDER; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 84971322212     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-1-1     Document Type: Review

References (24)

1. Reuß M: Gesundheitsindustrie - ein Wachstumsmarkt am Beispiel Dialyse. 2007 [http://www.fh-wuerzburg.de/fbw/media/artikel_downloads/c7ffd7461a_Fresenius.pdf].
2. Emminger HA, Kia T: Exaplan: Das Kompendium der klinischen Medizin. München 2008.
3. Fliser D, Ritz E: Störung des Kalzium- und Phosphathaushalts. Urologe 1999, 38:285.
4. Hutchison AJ: Oral phosphate binders. Kidney Int 2009, 75:906-914.
5. Nöcker HG: Sterblichkeitsrisiko bei langfristigem Einsatz von Sevelamer deutlich geringer. [http://209.85.129.132/search?q=cache:2_kk0C_u4MIJ: www.presseportal.de/pm/38681/712916/genzyme_gmbh+n%C3%B6cker +Sterblichkeitsrisiko+bei+langfristigem+Einsatz+von+Sevelamer+deutlich +geringer&cd = 2&hl=de&ct=clnk&gl=de].
6. Brunner-Ziegler S, Fröschl B, Hiebinger C, et al: Effektivität und Kosteneffizienz von Phosphatbindern in der Dialyse. In Deutsches Institut für Medizinische Dokumentation und Information (DIMDI), Schriftenreihe Health Technology Assessment (HTA) in der Bundesrepublik Deutschland. Volume 87. HTA-Bericht Köln; 2009, [http://portal.dimdi.de/de/hta/hta_berichte/hta236_bericht_de.pdf].
7. Navaneethan SD, Palmer SC, Craig JC, et al: Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials. Am J Kidney Dis 2009, 54:619-637.
8. Tonelli M, Pannu N, Manns B: Oral Phosphate Binders in Patients with Kidney Failure. N Engl J Med 2010, 362:1312-1324.
9. Qunibi W, Moustafa M, Muenz LR: A 1-Year Randomized Trial of Calcium Acetate Versus Sevelamer on Progression of Coronary Artery Calcification in Hemodialysis Patients With Comparable Lipid Control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) Study. Am J Kidney Dis 2008, 51:952-965.
10. Emmett M: A Comparison of Calcium-Based Phosphorus Binders for Patients with Chronic Kidney Disease. Dial Transplant 2006, 35:284-293.
11. Huybrechts KF, Caro JJ, Wilson DA: Health and Economic Consequences of Sevelamer Use for Hyperphosphatemia in Patients on Hemodialysis. Value Health 2005, 8:549-560.
12. de Francisco ALM, Leidig M, Covic AC, et al: Evaluation of calcium acetate/ magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010, 25:3707-3717.
13. Deuber HJ: Verbessertes Phosphat-Management durch Phosphatbinder. Dialyse aktuell 2002, 3:1-3.
14. 2+ im Kalzium-, Phosphat und sHPT-Management. Nieren- und Hochdruckkrankheiten 2008, 37:260-278.
15. Manns B, Klarenbach S, Lee H, et al: Economic evaluation of Sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007, 22:2867-2878.
16. Meema HE, Oreopoulos DG, Rapoport A: Serum magnesium level and arterial calcification in end-stage renal disease. Kidney International 1987, 32:388-394.
17. Turgut F, Kanbay M, Metin: Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008, 40:1075-1082.
18. Tzanakis IP, Wei M: Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008, 40:193-201.
19. Ishimura E, Okuno S, Kitatani K: Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clinical Nephrology 2007, 68:222-227.
20. Spiegel DM, Farmer B: Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. Hemodial Int 2009, 13:453-459.
21. Lacson EK, Wang W, Lazarus M: Magnesium and Mortality Risk in Hemodialysis Patients. J Am Soc Nephrol 2009, 20:453A.
22. Kanbay M, Goldsmith D, Uyar ME: Magnesium in Chronic Kidney Disease: Challenges and Opportunities. Blood Purif 2010, 29:280-292.
23. Deuber HJ: Long-term efficacy and safety of an oral phosphate binder containing both calcium and magnesium carbonate in hemodialysis patients. Nieren- und Hochdruckkrankheiten 2004, 33:403-408.
24. Suki WN, Zabaneh R, Cangiano JL: Effects of Sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney International advance online publication 2007, 71:438-441.